New aTyr Class Action Expands Investor Window Following EFZO‑FIT Trial Failure

Overview

• Hagens Berman filed King v. aTyr Pharma in the Southern District of California, expanding the proposed class period to November 7, 2024 through September 12, 2025.
• Faruqi & Faruqi and Levi & Korsinsky issued notices or investigations, with some actions referencing a shorter class period beginning January 16, 2025.
• Investors seeking to serve as lead plaintiff must move by December 8, 2025 under the Private Securities Litigation Reform Act.
• The complaints allege that aTyr and certain executives made overly positive statements while concealing adverse facts about efzofitimod’s ability to enable complete steroid tapering.
• aTyr disclosed on September 15 that EFZO‑FIT failed its primary endpoint, reported steroid‑dose changes favoring placebo and a modest withdrawal difference, the stock fell about 83%, and the company said it would consult the FDA.